Palisade Asset Management LLC trimmed its position in Eli Lilly And Co (NYSE:LLY) by 1.0% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 25,664 shares of the company’s stock after selling 270 shares during the period. Palisade Asset Management LLC’s holdings in Eli Lilly And Co were worth $2,870,000 at the end of the most recent quarter.
Several other large investors have also recently made changes to their positions in LLY. Enterprise Trust & Investment Co bought a new position in shares of Eli Lilly And Co during the 3rd quarter worth approximately $27,000. Prestige Wealth Management Group LLC bought a new position in shares of Eli Lilly And Co in the second quarter valued at $34,000. Meridian Wealth Management LLC bought a new position in shares of Eli Lilly And Co in the first quarter valued at $38,000. Manchester Financial Inc. bought a new position in shares of Eli Lilly And Co in the second quarter valued at $40,000. Finally, Litman Gregory Asset Management LLC bought a new position in shares of Eli Lilly And Co in the second quarter valued at $47,000. Institutional investors and hedge funds own 76.79% of the company’s stock.
In other news, SVP Stephen F. Fry sold 9,452 shares of Eli Lilly And Co stock in a transaction on Thursday, September 5th. The stock was sold at an average price of $115.00, for a total transaction of $1,086,980.00. Following the completion of the sale, the senior vice president now owns 100,211 shares of the company’s stock, valued at $11,524,265. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Alfonso G. Zulueta sold 19,500 shares of Eli Lilly And Co stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $112.91, for a total value of $2,201,745.00. Following the sale, the senior vice president now directly owns 38,306 shares of the company’s stock, valued at approximately $4,325,130.46. The disclosure for this sale can be found here. Insiders have sold a total of 243,452 shares of company stock valued at $28,252,925 in the last ninety days. Insiders own 0.11% of the company’s stock.
Eli Lilly And Co stock traded up $0.95 during mid-day trading on Thursday, hitting $108.90. 712,041 shares of the company’s stock traded hands, compared to its average volume of 2,973,723. The firm has a 50 day simple moving average of $111.29 and a two-hundred day simple moving average of $114.23. Eli Lilly And Co has a fifty-two week low of $104.17 and a fifty-two week high of $132.13. The stock has a market cap of $104.17 billion, a price-to-earnings ratio of 19.62, a P/E/G ratio of 1.87 and a beta of 0.16. The company has a debt-to-equity ratio of 4.98, a current ratio of 1.13 and a quick ratio of 0.87.
Eli Lilly And Co (NYSE:LLY) last announced its quarterly earnings results on Tuesday, July 30th. The company reported $1.50 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.45 by $0.05. Eli Lilly And Co had a return on equity of 70.86% and a net margin of 33.76%. The business had revenue of $5.64 billion during the quarter, compared to the consensus estimate of $5.59 billion. During the same quarter last year, the firm posted $1.48 EPS. The company’s quarterly revenue was up .9% on a year-over-year basis. On average, research analysts anticipate that Eli Lilly And Co will post 5.72 earnings per share for the current fiscal year.
Several equities analysts recently weighed in on the stock. UBS Group decreased their target price on shares of Eli Lilly And Co from $134.00 to $133.00 and set a “buy” rating for the company in a research note on Thursday. Bank of America assumed coverage on shares of Eli Lilly And Co in a research note on Wednesday. They issued a “buy” rating and a $133.00 target price for the company. Finally, ValuEngine cut shares of Eli Lilly And Co from a “buy” rating to a “hold” rating in a research note on Friday, June 28th. Eight analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. Eli Lilly And Co has an average rating of “Buy” and an average target price of $127.69.
Eli Lilly And Co Profile
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Featured Story: NASDAQ
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).
Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.